Find in Library

Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia

oleh: Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Olga Eissymont, Martina Crysandt, Martin Görner, Sabine Kayser, Stefan Krause, Christoph Schliemann, Tobias Gaska, Martin Kaufmann, Jens Chemnitz, Markus Schaich, Alexander Hoellein, Uwe Platzbecker, Meinhard Kieser, Carsten Müller-Tidow, Richard F. Schlenk